SHH and neoplasm: Although once regarded as a single tumour entity, it is now widely accepted that there are four distinct molecular subgroups of medulloblastoma (WNT, SHH, Group 3, and Group 4), which differ in their patient demographics, metastatic potential, and prognosis2,3.